156 related articles for article (PubMed ID: 31841301)
21. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor.
Razi-Wolf Z; Galvin F; Gray G; Reiser H
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11182-6. PubMed ID: 7504299
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering.
Sandström K; Xu Z; Forsberg G; Nygren PA
Protein Eng; 2003 Sep; 16(9):691-7. PubMed ID: 14560055
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice.
Matsumoto T; Sasaki N; Yamashita T; Emoto T; Kasahara K; Mizoguchi T; Hayashi T; Yodoi K; Kitano N; Saito T; Yamaguchi T; Hirata K
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1141-51. PubMed ID: 27055906
[TBL] [Abstract][Full Text] [Related]
24. A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro.
Srinivasan M; Wardrop RM; Gienapp IE; Stuckman SS; Whitacre CC; Kaumaya PT
J Immunol; 2001 Jul; 167(1):578-85. PubMed ID: 11418697
[TBL] [Abstract][Full Text] [Related]
25. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
[TBL] [Abstract][Full Text] [Related]
26. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
27. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex.
Garrett-Thomson SC; Massimi A; Fedorov EV; Bonanno JB; Scandiuzzi L; Hillerich B; Seidel RD; Love JD; Garforth SJ; Guha C; Almo SC
PLoS One; 2020; 15(6):e0233578. PubMed ID: 32497097
[TBL] [Abstract][Full Text] [Related]
29. A theoretical framework for quantitative analysis of the molecular basis of costimulation.
Jansson A; Barnes E; Klenerman P; Harlén M; Sørensen P; Davis SJ; Nilsson P
J Immunol; 2005 Aug; 175(3):1575-85. PubMed ID: 16034096
[TBL] [Abstract][Full Text] [Related]
30. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.
Tseng SY; Otsuji M; Gorski K; Huang X; Slansky JE; Pai SI; Shalabi A; Shin T; Pardoll DM; Tsuchiya H
J Exp Med; 2001 Apr; 193(7):839-46. PubMed ID: 11283156
[TBL] [Abstract][Full Text] [Related]
31. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel MF; Allison JP
J Exp Med; 1995 Aug; 182(2):459-65. PubMed ID: 7543139
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells.
Kubin M; Kamoun M; Trinchieri G
J Exp Med; 1994 Jul; 180(1):211-22. PubMed ID: 7516408
[TBL] [Abstract][Full Text] [Related]
33. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
34. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
35. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
van der Merwe PA; Bodian DL; Daenke S; Linsley P; Davis SJ
J Exp Med; 1997 Feb; 185(3):393-403. PubMed ID: 9053440
[TBL] [Abstract][Full Text] [Related]
36. Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens.
Yi-qun Z; Joost van Neerven RJ; Kasran A; de Boer M; Ceuppens JL
Int Immunol; 1996 Jan; 8(1):37-44. PubMed ID: 8671587
[TBL] [Abstract][Full Text] [Related]
37. Utilization of multiple phage display libraries for the identification of dissimilar peptide motifs that bind to a B7-1 monoclonal antibody.
De Ciechi PA; Devine CS; Lee SC; Howard SC; Olins PO; Caparon MH
Mol Divers; 1996 Feb; 1(2):79-86. PubMed ID: 9237196
[TBL] [Abstract][Full Text] [Related]
38. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses.
Roy M; Aruffo A; Ledbetter J; Linsley P; Kehry M; Noelle R
Eur J Immunol; 1995 Feb; 25(2):596-603. PubMed ID: 7533092
[TBL] [Abstract][Full Text] [Related]
39. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.
Schwartz JC; Zhang X; Fedorov AA; Nathenson SG; Almo SC
Nature; 2001 Mar; 410(6828):604-8. PubMed ID: 11279501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
